Moderna’s mRNA flu vaccine passes FDA AdCom, review underway

Moderna’s mRNA-based influenza vaccine candidate has successfully passed a review by the U.S. Food and Drug Administration's (FDA) Advisory Committee (AdCom). This milestone marks a significant step forward for the application of messenger RNA technology beyond COVID-19 and into the seasonal respiratory virus market. The ongoing regulatory review will determine if this candidate becomes the first mRNA flu vaccine to reach the commercial market, potentially disrupting the traditional egg-based manufacturing landscape.